Abstract:Background: Dendritic cell (DC) targeted antigen delivery is a promising strategy to enhance vaccine efficacy and delivery of therapeutics. Self-assembling peptide-based nanoparticles and virus-like particles (VLPs) have attracted extensive interest as non replicating vectors for nanovaccine design, based on their unique properties, including molecular specificity, biodegradability and biocompatibility. DCs are specialized antigen-presenting cells involved in antigen capture, processing, and presentation to initiate adaptive immune responses. Using DC-specific ligands for targeted delivery of antigens to DCs may be utilized as a promising strategy to drive efficient and strong immune responses. Methods: In this study, several candidates for DC-binding peptides (DCbps) were individually integrated into C-terminal of porcine circovirus type 2 (PCV2) Cap, a viral protein that could self-assemble into icosahedral VLPs with 60 subunits. The immunostimulatory adjuvant activity of DC-targeted VLPs was further evaluated in a vaccine model of PCV2 Cap. Results: With transmission electron microscopy (TEM), E. coli expressed Cap-DCbp fusion proteins were observed self-assembled into highly ordered VLPs. Further, in dynamic light scattering (DLS) analysis, chimeric VLPs exhibited similar particle size uniformity and narrow size distribution as compared to wild type Cap VLPs. With a distinctly higher targeting efficiency, DCbp3 integrated Cap VLPs (Cap-DCbp3) displayed enhanced antigen uptake and increased elicitation of antigen presentation-related factors in BM-DCs. Mice subcutaneously immunized with Cap-DCbp3 VLPs exhibited significantly higher levels of Cap-specific antibodies, neutralizing antibodies and intracellular cytokines than those with other DCbp integrated or wild type Cap VLPs without any DCbp. Interestingly, Cap-DCbp3 VLPs vaccine induces robust cellular immune response profile, including the efficient production of IFN-gamma, IL-2 and IL-10. Meanwhile, the improved proliferation index in lymphocytes with Cap-DCbp3 was also detected as compared to other VLPs. Conclusion: This study described the potential of DC-binding peptides for further improved antigen delivery and vaccine efficacy, explainning nanovaccine optimization in relation to a range of emerging and circulating infectious pathogens.

Self‐Assembled Virus‐Like Particle Vaccines via Fluorophilic Interactions Enable Infection Mimicry and Immune Protection (Adv. Healthcare Mater. 32/2023)

Self‐Assembled Virus‐like Particle Vaccines via Fluorophilic Interactions Enable Infection Mimicry and Immune Protection

Virus-Like Particle-Templated Silica-Adjuvanted Nanovaccines with Enhanced Humoral and Cellular Immunity

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

Virus-like particles as powerful vaccination strategy against human viruses

Virus-Like Particle Engineering: From Rational Design to Versatile Applications

Bacterial superglue enables easy development of efficient virus-like particle based vaccines

A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles

Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses

Dendritic cell targeting virus-like particle delivers mRNA for in vivo immunization

Flower-like mesoporous silica nanoparticles as an antigen delivery platform to promote systemic immune response

Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers

Virus-like particles: flexible platforms for vaccine development

A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy

[Current research status of virus-like particle vaccine]

Vaccine Platforms: Biosynthesis of Self‐Assembled Proteinaceous Nanoparticles for Vaccination (Adv. Mater. 42/2020)

Assessing Sequence Plasticity of A Virus-Like Nanoparticle by Evolution Toward A Versatile Scaffold for Vaccines and Drug Delivery

Virus-like Particle Vaccines and Platforms for Vaccine Development

Bio-mimic particles for the enhanced vaccinations: Lessons learnt from the natural traits and pathogenic invasion

An Ultrastable Virus‐Like Particle with a Carbon Dot Core and Expanded Sequence Plasticity